The Relative Strength (RS) Rating for Harmony Biosciences climbed into a new percentile Friday, with an increase from 79 to 83.
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the market's biggest winners often have an 80 or better RS Rating as they begin their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Harmony Biosciences is working on a cup without handle with a 41.61 buy point. See if it can clear the breakout price in heavy trading.
The company showed 6% EPS growth in the latest quarterly report. Sales increased 16%.
Harmony Biosciences holds the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
